Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of health-care company Centene
So what: Barclays Capital analyst Joshua Raskin upgraded the company from underweight to overweight, showing a big change of heart. Raskin thinks a favorable environment in Medicaid will give the company a boost, so he put a $32 price target on shares.
Now what: The classic analyst bump hit Centene, but after the spike, the stock has settled lower, up just 6% for the day right now. With a price-to-earnings ratio of 14.5, Centene is providing a good value, but investors may want to wait for today's bump to fade before jumping in. I'll give the stock a day or two to settle down, instead of buying on a day when an analyst is moving the stock.
Interested in more info on Centene? Add it to your watchlist.
Fool contributor Travis Hoium does not have a position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings, or follow his Motley Fool CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.